Shots:

• Alexion and Caelum collaborate for the development of CAEL-101 in PIa/Ib trial and Caelum to receive $60M as an equity investment- near-term milestones & will conduct P-II trial for CAEL-101 to treat Light Chain (AL) Amyloidosis
• Post-P-II study completion- Alexion will get an exclusive option to acquire Caelum- depending on the results of CAEL-101 in P-II. If the option is exercised- Caelum will receive $500M- including upfront- milestones- and royalties from Alexion
• CAEL-101 is a mAb- targeted for reducing and eliminating amyloid accumulation in patients with AL- has received FDA’s ODD for AL amyloidosis has shown improved results in P-Ia/Ib study for patients with r/r AL amyloidosis

Ref: Business Wire | Image: Business Wire